Karen S. Wilcox
Professor of Pharmacology and Toxicology
Neurobiology of Disease
B.A. 1981, Allegheny College; Ph.D. 1993, University of Pennsylvania
Electrophysiological mechanisms of action of novel anticonvulsant drugs
The Wilcox laboratory is interested in understanding basic mechanisms underlying epileptogenesis, seizure generation, and therapy-resistance to anticonvulsant drugs. To achieve these goals, we use electrophysiology (patch clamping and EEG), calcium imaging, pharmacology, behavioral paradigms, genetically modified animals, and immunohistochemical techniques in a variety of in vitro preparations and animal models of epilepsy. Our working hypothesis is that insight into disease-induced changes in neuronal and glial function will provide new avenues for therapeutic interventions in patients at risk for developing epilepsy or those patients who are refractory to current treatment options. To that end, I am also the Principal Investigator of the Anticonvulsant Drug Development (ADD) Program and direct studies determining the anti-seizure potential of proprietary investigational compounds through a contract with NINDS at the National Institutes of Health.